MoonLake Immunotherapeutics (MLTX) Research & Development (2021 - 2026)

MoonLake Immunotherapeutics' Research & Development history runs 6 years deep, the most recent figure standing at $54.5 million for Q1 2026.

• On a quarterly basis, Research & Development rose 49.52% year-over-year to $54.5 million in Q1 2026; TTM through Mar 2026 was $220.9 million, a 62.18% increase from a year earlier, with the FY2025 full-year figure at $202.9 million, up 79.89% from the prior year.
• Research & Development eased to $54.5 million in Q1 2026 per MLTX's latest filing, from $56.0 million in the prior quarter.
• Across five years, Research & Development topped out at $60.6 million in Q3 2025 and bottomed at $7.4 million in Q1 2023.
• The 5-year median for Research & Development is $13.0 million (2024), against an average of $26.1 million.
• Biggest YoY gain for Research & Development was 1247.88% in 2022; the steepest drop was 68.0% in 2022.
• Year by year, Research & Development stood at $11.4 million in 2022, then dropped by 28.77% to $8.1 million in 2023, then jumped by 398.39% to $40.4 million in 2024, then soared by 38.77% to $56.0 million in 2025, then decreased by 2.66% to $54.5 million in 2026.
• Per Business Quant, the three latest MLTX Research & Development figures stand at $54.5 million (Q1 2026), $56.0 million (Q4 2025), and $60.6 million (Q3 2025).